On 5 May 2017, the European Centre for Disease Prevention and Control (ECDC) published its updated protocol for surveillance of healthcare-associated infections (HAIs) and prevention indicators in European intensive care units (ICUs) \[[@CR1]\]. The ECDC's Healthcare-Associated Infections surveillance Network (HAI-Net) has been coordinating European surveillance of HAIs in ICUs since 2008 with participation of 15 countries and 1365 ICUs in 2015 \[[@CR2]\]. The methodology was originally developed by the Hospitals in Europe Link for Infection Control through Surveillance (HELICS) project in 2000--2002 \[[@CR3]\] and adopted by ECDC in 2010. A revision of the first protocol was agreed at consensus expert meetings in 2013--2015.

The objective of the ECDC surveillance protocol is the standardisation of case definitions, data collection and reporting procedures for hospitals participating in national or regional surveillance of HAIs in ICUs across Europe in order to facilitate the collection of comparable epidemiological data as a basis for interventions and the communication and exchange of experience of national surveillance systems. The case definitions of HAIs aim to accommodate differences, across Europe, in diagnostic practices such as taking microbiological samples for the diagnosis of HAIs. The minimal requirement for participation in surveillance of HAIs in ICUs is surveillance of bloodstream infections (BSIs) and pneumonia (PN). Reporting of urinary tract infections (UTIs) and catheter-related infections (CRIs) is optional. The data are collected by the national surveillance systems and submitted annually to ECDC. The results are published on the ECDC website \[[@CR2]\]. A software application, HelicsWin.Net, is available free-of-charge for entry of HAI surveillance data (<https://ecdc.europa.eu/en/publications-data/helicswinnet-hwn>).

The latest update of the ECDC protocol was triggered by the unexplained, large variation in the prevalence of HAIs among European countries reported by the ECDC point prevalence survey of HAIs and antimicrobial use in European acute care hospitals 2011--2012. Structure and process indicators for infection prevention and control and antimicrobial stewardship (Table [1](#Tab1){ref-type="table"}), as well as a new variable on the outcome of the HAI were included in the latest version of the surveillance protocol. These modifications were developed by ECDC and HAI-Net ICU experts and agreed during an HAI-Net ICU meeting in February 2015.Table 1Structure and process indicators for infection prevention control and antimicrobial stewardship in intensive care units (ICUs)AreaIndicatorMetricHand hygieneAlcohol hand rub consumption in ICU during the previous yearLitres per 1000 patient-daysStaffingRegistered nurse hours in ICUHours per 1000 patient-daysNursing assistant hours in ICUHours per 1000 patient-daysAntimicrobial stewardshipReview antimicrobial therapy within 72 hProportion (%) compliant observationsIntubationEndotracheal pressure controlled and/or corrected at least twice a dayProportion (%) compliant observationsOral decontamination using oral antiseptics at least twice a dayProportion (%) compliant observationsPosition of the patient*not* supineProportion (%) compliant observationsCentral venous catheterCatheter site dressing is*not* damp, loose or visibly soiledProportion (%) compliant observations

The ECDC case definitions applied for surveillance of HAIs in European ICUs are presented in Table 1a in the supplementary material.

The case definition for BSI addresses both primary and secondary BSIs. A definition for CRI establishes the microbiological criteria for assignment of the catheter as the origin of the BSI. When CRIs are not specifically reported, BSIs for which the same microorganism was cultured from the catheter or when symptoms improved within 48 h after removal of the catheter are reported as BSIs with origin central venous catheter (CVC). In this way, it is possible to assess the burden of BSIs linked to catheters in ICUs with different local practices for microbiological confirmation through culture of the catheter tip or taking blood samples through the catheter for quantitative culture or differential time to positivity. This definition differs from the definition of the National Healthcare Safety Network of the US Centers for Disease Control and Prevention (CDC/NHSN) of central line-associated bloodstream infection (CLA-BSI) that includes all primary BSIs with a central line in place for at least 2 days on the date of the BSI \[[@CR4]\]. However, it is possible to calculate CLA-BSI rates with HAI-Net ICU data to perform comparisons with data from the US and other surveillance networks that use this definition. The definitions for CRI and BSI with origin CVC were preferred, as they avoid incriminating the catheter for BSI cases with unidentified origin. Such cases may be the result of translocation or a difficult to confirm source and linking them to a central vascular catheter may lead to overestimation of the incidence and dilute the effect of preventive interventions \[[@CR5]\]. The CRI definition has been applied in studies that assess the effect of prevention efforts \[[@CR6]\].

For pneumonia, the ECDC case definition (based on the 2002 NHSN definition) applies imaging, clinical and microbiological criteria and consists of five levels (PN1--PN5), from PN1 requiring microbiological confirmation from minimally contaminated specimens to PN5 requiring no positive microbiological data. These levels address differences in diagnostic practices across Europe and intend to ensure comprehensiveness and inform the interpretation of the results. The definitions primarily aim to support infection prevention and control but they also encourage microbiological confirmation that may impact clinical management in terms of treatment decisions and especially antimicrobial use. The definition for ventilator-associated pneumonia (VAP) differs from the current CDC/NHSN definition of ventilator-associated events (VAE), which was implemented in the USA in 2013 \[[@CR5]\]. HAI-Net maintained the previous definition for pneumonia and VAP, as it was considered more relevant from both clinical and prevention perspectives. The definition is in line with the one used in prevention studies and diagnostic and treatment guidelines and has been used in studies that demonstrate the effect of preventive interventions \[[@CR7]\]. Furthermore, a recent meta-analysis indicated that VAE surveillance does not detect cases of VAP accurately \[[@CR8]\]. A comparison with the current CDC/NHSN definition of VAE and probable VAP \[[@CR4]\] showed discordance for VAP, with agreement in only four of 61 cases identified as VAP by either one or the other definition \[[@CR9]\]. In contrast, a study comparing the ECDC definition with the previous US definition for VAP had demonstrated very high concordance when applying both definitions in the same group of patients \[[@CR10]\].

The updated ECDC protocol for surveillance of HAIs in European ICUs combines outcome indicators (incidence of HAIs, microbiology and outcome) with structure and process indicators for infection prevention and control and antimicrobial stewardship. It aims to provide information that is useful and actionable at hospital, regional and national level both for prevention of HAIs and policymaking. EU/EEA countries are invited to apply the protocol in national surveillance systems and participate in European surveillance fostering an EU-wide collaboration to support the prevention of HAIs.
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